Quantitative structural MRI for early detection of Alzheimer's disease.
Quantitative structural MRI for early detection of Alzheimer's disease.
复制标题
DOI：
10.1586/ern.10.162
复制
发表时间：
2010-11
影响因子：
4.3
通讯作者：
Brewer JB
中科院分区：
文献类型：
--
作者：
McEvoy LK;Brewer JB
阿尔茨海默氏病（AD）是一种常见的进行性神经退行性疾病，直到患者达到痴呆阶段才被诊断。迫切需要在早期阶段识别AD，以便在可用时能够早期开始治疗。定量结构MRI对轻度和临床前AD中发生的神经退行性变敏感，并且可以预测轻度认知障碍个体的痴呆程度下降。一旦潜在的积极的、改善疾病的治疗方法可用，持续性脑萎缩的客观证据将对风险/获益决策至关重要。最近的进展为定量结构MRI在临床实践中的应用铺平了道路，并且最初的临床应用是有希望的。然而，需要在临床实践中观察到的相对较少的患者人群中进一步经验这些措施，以完成将最近AD科学知识的巨大进步转化为临床领域。
Alzheimer’s disease (AD) is a common progressive neurodegenerative disorder that is not currently diagnosed until a patient reaches the stage of dementia. There is a pressing need to identify AD at an earlier stage, so that treatment, when available, can begin early. Quantitative structural MRI is sensitive to the neurodegeneration that occurs in mild and preclinical AD, and is predictive of decline to dementia in individuals with mild cognitive impairment. Objective evidence of ongoing brain atrophy will be critical for risk/benefit decisions once potentially aggressive, disease-modifying treatments become available. Recent advances have paved the way for the use of quantitative structural MRI in clinical practice, and initial clinical use has been promising. However, further experience with these measures in the relatively unselected patient populations seen in clinical practice is needed to complete translation of the recent enormous advances in scientific knowledge of AD into the clinical realm.
登录
查看更多内容
影响因子：
2.8
作者：
Brewer JB
通讯作者：
Brewer JB
影响因子：
7
作者：
Braak, H;Braak, E
通讯作者：
Braak, E
影响因子：
--
作者：
Bell-McGinty, S;Lopez, OL;Becker, JT
通讯作者：
Becker, JT
影响因子：
4
作者：
Blennow, Kaj;Zetterberg, Henrik
通讯作者：
Zetterberg, Henrik
影响因子：
5.7
作者：
Dale, AM;Fischl, B;Sereno, MI
通讯作者：
Sereno, MI